PROPANC BIOPHARMA INC

Propanc Biopharma shares tumble 13%, below 200‑day MA amid clinical‑stage uncertainty and thin OTC liquidity—investors watch for upcoming milestones.

Propanc Biopharma stock drops 7.3% to $0.32, a 49% decline since last month, amid weak liquidity and a bearish 200‑day trend. Investors gauge upcoming clinical data for recovery.